MEDIPOST has made a request to conduct phase 1.2a clinical trial using ‘NEUROSTEM-AD’ a treatment agent for Alzheimer’s disease using stem cells on June 28 to the FDA.
This study is receiving attention from various academies and ministries of the health of various countries in the era of difficulties with the development of treatment for Alzheimer’s disease, as it is the first in the world to use stem cells.
MEDIPOST successfully conducted the phase 1 clinical trial using ‘NEUROSTEM-AD’ between November 2010 and December 2011, and has since been conducting additional preclinical studies for the next year to study the routes of administration and methods.
Unlike the administration of NEUROSTEM-AD through surgery into the brain once, during the first clinical trial, in the 1.2a clinical trial, they have changed the method to the administration to cerebrospinal fluid three times to improve the patient convenience.
Once the approval for clinical trial for NEUROSTEM-AD is given, MEDIPOST will be investigating the efficacy and safety of this agent together with the Samsung Seoul Medical Center for the next 2 years.